IGFBP7 ratio for HFpEF

A method for diagnosing heart failure with preserved ejection fraction (HFpEF) in a subject suspected of suffering from HFpEF, said method comprising the steps of

• (a) determining the amounts of IGFBP7 (Insulin-like growth factor-binding protein 7), of a BNP-type peptide, and of CRP (C-reactive protein) in a blood, serum or plasma sample from the subject,
• (b) calculating a ratio of the sum of the amounts of IGFBP7 and CRP and the amount of the BNP-type peptide,
• (c) comparing the ratio calculated in step (b) with a reference ratio,
• (d) diagnosing heart failure with preserved ejection fraction, and
• (e) administering at least one medicament to the subject suspected of suffering from HFpEF, wherein the at least one medicament is selected from the group consisting of a sodium-glucose cotransporter-2 inhibitor, a soluble guanylate cyclase stimulator, an inorganic nitrate, an angiotensin receptor-neprilysin inhibitor, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, beta adrenergic blockers, aldosterone antagonists, and diuretics.

A method for differentiating between heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) in a subject suffering from heart failure, said method comprising the steps of

• (a) receiving a blood, serum or plasma sample from the subject,
• (b) determining the amounts of IGFBP7 (Insulin-like growth factor-binding protein 7), of a BNP-type peptide and of CRP (C-reactive protein) in the sample,
• (c) providing a value for a ratio of the sum of the amounts of IGFBP7 and CRP and the amount of the BNP-type peptide to the attending physician, thereby allowing the differentiation between HFpEF and HfrEF, and
• (d) administering at least one medicament to the subject suffering from heart failure, wherein the at least one medicament is selected from the group consisting of a sodium-glucose cotransporter-2 inhibitor, a soluble guanylate cyclase stimulator, an inorganic nitrate, an angiotensin receptor-neprilysin inhibitor, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, beta adrenergic blockers, aldosterone antagonists, and diuretics.

A method for diagnosing heart failure with preserved ejection fraction (HFpEF) in a subject suspected of suffering from HFpEF, said method comprising the steps of

• (a) receiving a blood, serum or plasma sample from the subject,
• (b) determining the amounts of IGFBP7 (Insulin-like growth factor-binding protein 7), of a BNP-type peptide and of CRP (C-reactive protein) in the sample, and
• (c) providing a value for a ratio of the sum of the amounts of IGFBP7 and CRP and the amount of BNP-type peptide to the attending physician, thereby allowing the diagnosis of HFpEF, and
• (d) administering at least one medicament to the subject suspected of suffering from HFpEF, wherein the at least one medicament is selected from the group consisting of a sodium-glucose cotransporter-2 inhibitor, a soluble guanylate cyclase stimulator, an inorganic nitrate, an angiotensin receptor-neprilysin inhibitor, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, beta adrenergic blockers, aldosterone antagonists, and diuretics.